Regulatory Q&A Forum

With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities must now designate a U.S. Agent to comply with new FDA facility registration and product l...

For medical device manufacturers utilizing an external 'Person Responsible for Regulatory Compliance (PRRC) as a Service' under EU MDR, how can they ensure their provider not only meets the baseline r...

As non-EU manufacturers prepare for evolving chemical regulations with an eye toward the 2026 timeframe, how can they conduct a thorough due diligence process to select a reliable and competent REACH ...

With the 2026 abolition of France's VAT Regime 42 set to mandate the appointment of a fiscal representative for many non-EU businesses, how can a company develop a realistic budget and accurately fore...

With significant updates to the EU WEEE Directive and the introduction of the Packaging and Packaging Waste Regulation (PPWR) looming for 2026, how should a medical device manufacturer strategically e...

For non-EU manufacturers placing medical devices on the European market, selecting an EU Authorised Representative (AR) is a mandatory and strategic decision under the Medical Device Regulation (EU) 2...

When selecting a GDPR Article 27 Representative, what key criteria should a non-EU organization evaluate to ensure the provider is a strategic partner rather than just a passive mailbox? With the Euro...

For non-EU manufacturers preparing for EU Medical Device Regulation (MDR) compliance, appointing an EU Authorized Representative (AR) is a mandatory step. While the cost is a key consideration, pricin...

For foreign establishments preparing for the 2026 biennial registration renewal period, what is the detailed operational process for changing their designated U.S. Agent while ensuring zero disruption...

As the EU MDR framework matures, selecting an external Person Responsible for Regulatory Compliance (PRRC) is a critical decision. Looking ahead to 2026, with ongoing issuance of MDCG guidance and ant...

With significant updates to the EU’s environmental regulations, such as the WEEE Directive and the new Packaging and Packaging Waste Regulation (PPWR), expected around 2026, how should a manufacturer ...

With significant revisions to the ISO 10993 series anticipated around 2026, how should medical device manufacturers strategically adapt their biocompatibility evaluation process, moving beyond a simpl...

For medical device manufacturers based outside the United Kingdom, appointing a UK Responsible Person (UKRP) is a critical step for market access. While the fundamental requirement is understood, what...

For many Class II medical devices, General Controls alone are insufficient to provide a reasonable assurance of safety and effectiveness. To address this, the FDA establishes Special Controls, which a...

For sponsors of a novel Class II Software as a Medical Device (SaMD), what are the essential components of a comprehensive cybersecurity risk management plan required for a premarket submission? Beyon...

Under the EU Medical Device Regulation (MDR), the role of the Person Responsible for Regulatory Compliance (PRRC) is a critical function for ensuring a manufacturer's ongoing conformity. As the regula...